For instance, results of contemporary clinical trials investigating FGFR2 inhibition in cholangiocarcinoma, including infigratinib (NCT03773302) and futibatinib (NCT04093362), could perhaps be extrapolated to patients with FGFR2 fusion positive, KRAS wildtype PDAC. The gene discussed is FGFR2; the disease is cholangiocarcinoma.